By
Marie Lachâtre et al.
Published: March 2, 2016, 4:49 p.m.·
Tags:
Drug-resistant TB,
Treatment
We read with interest the correspondence by Caitlin Reed and colleagues, reporting a patient with a severe case of extensively drug-resistant (XDR) tuberculosis who was treated with bedaquiline and subsequently denied delamanid because of concerns over additive cardiac toxic effects.1 Here we report the case of a man with XDR tuberculosis who was treated with a regimen containing bedaquiline and delamanid in combination.
Read More →
